Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]Zr-DFO-TST001
- Development stage
- Unknown
- Lead developer
- Transcenta
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[89Zr]Zr-DFO-TST001 is a Claudin 18.2 (CLDN18.2)-targeting immuno-PET imaging probe developed by Transcenta Holding Limited. It consists of the recombinant humanized monoclonal antibody TST001 (osemitamab) conjugated to the positron-emitting radioisotope Zirconium-89 (89Zr) via a deferoxamine (DFO) chelator. The probe is designed for non-invasive molecular imaging to assess CLDN18.2 expression levels in patients with gastrointestinal tumors, such as gastric and gastroesophageal junction cancers. By binding specifically to CLDN18.2-expressing cells, it allows for the visualization of tumor accumulation and distribution using PET/CT, potentially aiding in patient selection for CLDN18.2-targeted therapies.
- Other names
- 89Zr-DFO-osemitamab89Zr-labeled TST001
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on [89Zr]Zr-DFO-TST001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [89Zr]Zr-DFO-TST001.